Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
Abstract Background Despite anti-VEGF therapy, some patients develop chronic diabetic macular edema. The objective of this study was to evaluate anatomic and visual outcomes of switching patients with chronic DME from intravitreal bevacizumab or ranibizumab to intravitreal aflibercept injection. Met...
Main Authors: | Kendra A. Klein, Tina S. Cleary, Elias Reichel |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-04-01
|
Series: | International Journal of Retina and Vitreous |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40942-017-0064-0 |
Similar Items
-
One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
by: Tran THC, et al.
Published: (2021-05-01) -
Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
by: Sławomir Liberski, et al.
Published: (2022-08-01) -
Influence of Intravitreal Therapy on Choroidal Thickness in Patients with Diabetic Macular Edema
by: Patricia Udaondo Mirete, et al.
Published: (2023-01-01) -
Clinical Application of Intravitreal Aflibercept Injection for Diabetic Macular Edema Comparing Two Loading Regimens
by: Yoo-Ri Chung, et al.
Published: (2023-03-01) -
Aflibercept compared with dexamethasone in diabetic macular edema
by: Rodolfo Garretón, et al.
Published: (2021-05-01)